Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBIT: 2021-2024

Historic EBIT for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to -$3.1 million.

  • ARS Pharmaceuticals' EBIT fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of -$3.1 million for FY2024, which is 95.43% up from last year.
  • ARS Pharmaceuticals' EBIT amounted to -$3.1 million in FY2024, which was up 95.43% from -$67.5 million recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' EBIT peaked at -$3.1 million during FY2024, and registered a low of -$67.5 million during FY2023.
  • In the last 3 years, ARS Pharmaceuticals' EBIT had a median value of -$35.5 million in 2022 and averaged -$35.4 million.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 90.11% in 2023, then skyrocketed by 95.43% in 2024.
  • ARS Pharmaceuticals' EBIT (Yearly) stood at -$19.5 million in 2021, then slumped by 82.56% to -$35.5 million in 2022, then slumped by 90.11% to -$67.5 million in 2023, then surged by 95.43% to -$3.1 million in 2024.